Before weighing the target, it helps to clarify the vehicle. Vanguard PRIMECAP Fund Admiral Shares (VPMAX) is not a stock or an exchange-traded fund (ETF). It is an actively managed, large- and mid-capitalization growth mutual fund advised by PRIMECAP Management Company, a relationship that dates back to 1984. The fund carries roughly $90 billion in net assets and a low expense ratio of about 0.27%. Its defining traits are exceptionally low portfolio turnover (around 4%) and a structure in which several portfolio managers independently oversee separate portions of the fund.
Unlike a single stock, VPMAX does not have a widely quoted sell-side price target of its own. Instead, analysts rate the individual companies the fund holds, and those targets can be aggregated to estimate where the fund might trade. According to data aggregating 168 stocks held in the portfolio, the average 12-month analyst price target for the fund's holdings equates to roughly $271.54, with a high estimate near $340.73 and a low near $205.21. That places $275 just above the consensus-derived figure and directly in the path of any continued rally — making it a natural, psychologically significant milestone for investors tracking the fund.
VPMAX has traded recently in the low-to-mid $220s, after reaching a 52-week high of $241.35 and a 52-week low of $174.07. The fund has delivered a roughly 20% gain year-to-date and more than doubled over the past five years, underscoring its strength during the growth-led market environment. Because mutual funds are priced once daily at net asset value (NAV) after the close, intraday "market open" signals matter less than for stocks; investors see a single updated price each trading day.
Several factors support a move toward $275. First, the fund's underlying holdings carry a consensus "Moderate Buy" rating — 147 buy ratings against 20 holds and a single sell — suggesting analysts remain broadly constructive on the names that drive VPMAX's returns. Second, the fund's long-term growth focus and concentrated exposure to technology and health care position it well if those sectors continue to lead the market. Third, its very low turnover means the portfolio is built to compound over years rather than chase short-term trades, a quality that has historically rewarded patient holders.
The main risks are concentration and valuation. PRIMECAP's growth orientation means VPMAX can lag sharply when investors rotate toward value stocks, small caps, or defensive sectors, or when mega-cap technology and health care names de-rate. After a multi-year advance, the fund is no longer trading at a discount to its own history, and any earnings disappointments among its largest positions could weigh disproportionately. The recent pullback from the $241 high is a reminder that even strong funds consolidate.
On the chart, the $241.35 52-week high is the first meaningful resistance the fund must reclaim to resume its uptrend. Above that, the round-number $250 level is the next psychological hurdle before $275 comes into view. On the downside, the low-to-mid $220s represent a near-term support zone, with the $200 area serving as a deeper, longer-term floor that has not been tested for some time. Reaching $275 would require clearing the prior high decisively and building sustained momentum rather than a single sharp spike.
For investors who want to track whether VPMAX and thousands of other funds and equities are gaining or losing momentum, Tickeron's AI Daily Buy/Sell Signals offer an automated way to monitor changing market conditions. The product uses artificial intelligence to continuously scan a broad universe of securities and generate Buy, Sell, or Hold signals based on technical behavior and AI-driven analysis. Traders can use these signals to spot emerging opportunities, keep an eye on existing positions, and identify shifting trends more efficiently than manual screening. Exploring these AI-generated signals may help investors stay ahead of the momentum shifts that determine whether a target like $275 comes within reach.
Can VPMAX reach $275? The evidence suggests it is a realistic but not guaranteed objective over an extended time frame. The fund's long-term growth discipline, strong five-year performance, and the broadly positive analyst outlook on its holdings all support the case, and $275 sits only modestly above the consensus-derived target. However, the fund's concentrated sector exposure, richer valuation after a prolonged rally, and the distance still needed from the recent pullback are genuine obstacles. Investors should monitor whether the fund can reclaim its $241.35 52-week high, whether technology and health care leadership persists, and how the underlying holdings' earnings hold up. No price target is assured, and a move to $275 would likely require both continued sector strength and patience rather than a sudden surge.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, VPMAX has been closely correlated with VFFSX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if VPMAX jumps, then VFFSX could also see price increases.
| Ticker / NAME | Correlation To VPMAX | 1D Price Change % | ||
|---|---|---|---|---|
| VPMAX | 100% | +1.08% | ||
| VFFSX - VPMAX | 91% Closely correlated | +0.87% | ||
| VFINX - VPMAX | 81% Closely correlated | +0.86% | ||
| VFIAX - VPMAX | 80% Closely correlated | +0.86% | ||
| FXAIX - VPMAX | 78% Closely correlated | +0.87% | ||
| FWMMX - VPMAX | 72% Closely correlated | +0.42% | ||
More | ||||